Figure 6d reveals that high CLDN22 expression was predominantly associated with higher tumor grade (G4), the ME subtype, IDH wild‐type status, and unmethylated MGMT promoter, suggesting its potential role as a molecular marker for tumor aggressiveness and specific glioma subtypes. Here, CLDN22 is linked to neoplasm.